Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178.

Abstract

The patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3). The effects of human anti-hANGPTL3 mainly inhibit lipoprotein lipase activity and… (More)
DOI: 10.1517/13543776.2013.842555

Topics

8 Figures and Tables

Cite this paper

@article{Nakajima2014AntibodiesTH, title={Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178.}, author={Katsuyuki Nakajima and Junji Kobayashi}, journal={Expert opinion on therapeutic patents}, year={2014}, volume={24 1}, pages={113-9} }